A US review panel on Thursday recommended loosening restrictions on multiple trendy peptides, endorsing proposals that specialized pharmacies be allowed to produce such substances despite alarm bells from medical experts over safety concerns. The panel recommendations are not binding, but the Food and Drug Administration historically has given them significant weight. And the positive votes are a rebuke of the agency's career scientists who urged maintaining restrictions over lacking data and safety concerns. Panel member Elizabeth Rebello, a pharmacist and anesthesiologist, told the committee she voted no on BPC-157 "because of the lack of efficacy data" and "safety concerns." Advertisement AdvertisementAdvertisement AdvertisementShould the peptides ultimately be added to the bulks list for compounding, that does not mean they are FDA-approved.